As an early funder of PepGen, we are pleased to share that PenGen has dosed the first person in its Phase 2 trial for Duchenne amenable to skipping exon 51. Initial data , including safety and dystrophin production, at the 5 mg/kg dose is expected mid-20.
Read the Press Release HERE